Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerodalcibep Dose Finding in Hypercholesterolemia
NCT03549260Phase 2Completed
- Sponsor
- LIB Therapeutics
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of lerodalcibep in hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), heterozygous familial hypercholesterolemia (HeFH), sponsored by LIB Therapeutics. Started May 2018; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT03549260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549260.